<DOC>
	<DOCNO>NCT00101231</DOCNO>
	<brief_summary>This phase I trial study side effect best dose flavopiridol treat patient relapsed refractory acute myeloid leukemia , acute lymphoblastic leukemia , chronic myelogenous leukemia . Drugs use chemotherapy , flavopiridol , work different way stop growth cancer cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Flavopiridol Treating Patients With Relapsed Refractory Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximal tolerable dose flavopiridol relapse refractory acute leukemia adult ( Stratum 1 ) child ( Stratum 2 ) . II . To define qualitative quantitative toxicity flavopiridol regard organ specificity , time course , predictability , reversibility . III . To determine preliminary clinical activity flavopiridol adult ( Stratum 1 ) child ( Stratum 2 ) use novel schedule acute leukemia . IV . To evaluate plasma cellular pharmacokinetics flavopiridol patient enrol study . SECONDARY OBJECTIVES : I . To measure pharmacodynamic measurement include effect cell cycle ; modulation bcl-2 , mcl-1 , XIAP , bax , RNA polymerase II phosphorylation ; signal via VEGF ( VEGF , VEGF-R1 , VEGF-R2 , HIF-1 ) , NF-Kappa B pathway , PI3kinase pathway ; correlate Css pharmacokinetic feature . II . To assess drug induce apoptosis acute leukemia cell vitro subsequent relationship clinical response base upon Css flavopiridol attain vivo . II . To determine increase inflammatory cytokine ( TNF-alpha , gamma-IFN , IL-6 IL-8 ) correlate pharmacokinetics , pharmacodynamics , laboratory ( decrease serum albumin ) clinical ( hypotension observe first administration flavopiridol ) parameter treatment . OUTLINE : This dose-escalation study . Patients stratify accord age group ( adult [ ≥ 18 year ] v pediatric [ 1-17 year ] ) . Patients receive flavopiridol intravenously ( IV ) 30 minute follow 4-hour infusion day 1-3 . Treatment repeat every 21 day 6 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 2 month 1 year every 6 month 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Histologically confirm diagnosis one following : Acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) meet 1 follow criterion : Refractory initial treatment ( stratum 1 ) Recurrent disease prior highdose chemotherapy without stem cell support ( stratum 1 ) Highrisk refractory disease define fail ≥ 2 regimen remission induction ( i.e. , twice induction failure ) ( stratum 2 ) Highrisk relaspsed disease define disease second great bone marrow relapse ( stratum 2 ) Chronic myelogenous leukemia blast crisis ( stratum 1 ) Myeloid lymphoid blast crisis respond progress prior highdose imatinib mesylate ( 600800 mg/day ≥ 2 week ) No acute promyelocytic leukemia Ineligible unwilling undergo potentially curative allogeneic autologous stem cell transplantation Patients relapse AML refractory reinduction therapy comprise active , intensive salvage regimen eligible CNS involvement allow provide residual leukemic cell cerebrospinal fluid intrathecal chemotherapy radiotherapy Performance status ECOG ≥ 2 patient &gt; 10 year age Performance status Lansky 50100 % patient ≤ 10 year age At least 8 week Bilirubin ≤ 2 time upper limit normal ( ULN ) * ( unless due Gilbert 's syndrome ) ALT AST ≤ 5 time ULN* Creatinine ≤ 2.0 mg/dL* ( stratum 1 ) Creatinine &gt; 1.3 time ULN ( stratum 2 ) LVEF ≥ 40 % echocardiogram MUGA ( stratum 1 ) Shortening fraction ≥ 28 % echocardiogram ( stratum 2 ) No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No history allergy study drug No active infection require IV antibiotic No serious medical psychiatric illness would preclude give informed consent limit survival No uncontrolled illness See Disease Characteristics Recovered prior immunotherapy treatmentrelated toxicity ( stratum 2 ) More 8 week since prior biological agent ( e.g. , monoclonal antibody ) ( stratum 2 ) See Disease Characteristics Recovered prior chemotherapy treatmentrelated toxicity ( stratum 2 ) More 24 hour since prior hydroxyurea ( patient highly proliferative disease ) * More 2 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) No concurrent chemotherapy Prior hydrea and/or steroid allow ( stratum 2 ) No concurrent hormone , except steroid adrenal failure infusional toxicity ( i.e. , cytokine release syndrome ) hormone nondiseaserelated condition ( e.g. , insulin diabetes ) See Disease Characteristics Recovered prior radiotherapy treatmentrelated toxicity ( stratum 2 ) More 2 week since prior radiotherapy No concurrent palliative radiotherapy Post stem cell transplant allow provided completion ≥ 4 month prior study entry evidence active acute chronic graft v host disease ( stratum 2 ) No concurrent investigational agent No concurrent chronic systemic anticoagulant therapy medical condition ( e.g. , deep vein thrombosis atrial fibrillation ) Concurrent heparin allow maintain central line patency ( i.e. , catheter flush ) No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>